References
1. Bartelink IH, Lalmohamed A, van Reij EML, et al. Association of
busulfan exposure with survival and toxicity after haemopoietic cell
transplantation in children and young adults: a multicentre,
retrospective cohort analysis. Lancet Haematol .
2016;3(11):e526-e536. doi:10.1016/S2352-3026(16)30114-4
2. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area
under the curve with veno-occlusive disease following BMT. Bone
Marrow Transplant . 1996;17(2):225-230.
http://www.ncbi.nlm.nih.gov/pubmed/8640171.
3. Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug
monitoring is essential for intravenous busulfan therapy in pediatric
hematopoietic stem cell recipients. Pediatr Transplant .
2011;15(6):580-588. doi:10.1111/j.1399-3046.2011.01529.x
4. Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning
and HLA-matched haemopoietic stem-cell transplantation in patients with
chronic granulomatous disease: a prospective multicentre study.Lancet . 2014;383(9915):436-448. doi:10.1016/S0140-6736(13)62069-3
5. Horn B, Baxter-Lowe L-A, Englert L, et al. Reduced intensity
conditioning using intravenous busulfan, fludarabine and rabbit ATG for
children with nonmalignant disorders and CML. Bone Marrow
Transplant . 2006;37(3):263-269. doi:10.1038/sj.bmt.1705240
6. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford
NHG. Busulfan in Infant to Adult Hematopoietic Cell Transplant
Recipients: A Population Pharmacokinetic Model for Initial and Bayesian
Dose Personalization. Clin Cancer Res . 2014;20(3):754-763.
doi:10.1158/1078-0432.CCR-13-1960
7. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in
pediatrics: a novel dosing to improve safety/efficacy for hematopoietic
progenitor cell transplantation recipients. Bone Marrow
Transplant . 2004;33(10):979-987. doi:10.1038/sj.bmt.1704446
8. Matsumoto K, Uchida N, Sakurai A, Taniguchi S, Morita K. Clinical
Application of the Dried Blood Spot Method in the Measurement of Blood
Busulfan Concentration. Biol Blood Marrow Transplant .
2016;22(11):1968-1973. doi:10.1016/j.bbmt.2016.07.008
9. Watanabe E, Nishikawa T, Ikawa K, et al. Trough level monitoring of
intravenous busulfan to estimate the area under the plasma drug
concentration–time curve in pediatric hematopoietic stem cell
transplant recipients. Int J Hematol . 2015;102(5):611-616.
doi:10.1007/s12185-015-1853-6
10. Kishimoto K, Hasegawa D, Irie K, et al. Pharmacokinetic analysis for
model‐supported therapeutic drug monitoring of busulfan in Japanese
pediatric hematopoietic stem cell transplantation recipients.Pediatr Transplant . 2020;24(4):1-7. doi:10.1111/petr.13696
11. Evaluation and Licensing Division; Pharmaceutical and Food Safety
Bureau; Ministry of Health; Labour and Welfare. Guideline on
Bioanalytical Method Validation in Pharmaceutical Development.
https://www.pmda.go.jp/files/000206209.pdf. Accessed December 30, 2020.
12. Kangarloo SB, Naveed F, Ng ESM, et al. Development and Validation of
a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed
Infusion Rate Dosing. Biol Blood Marrow Transplant .
2012;18(2):295-301. doi:10.1016/j.bbmt.2011.07.015
13. Tsujimoto S, Shirai R, Utano T, et al. Comparison of clonazepam and
levetiracetam in children for prevention of busulfan-induced seizure in
hematopoietic stem cell transplantation. Int J Hematol .
2020;111(3):463-466. doi:10.1007/s12185-019-02795-8
14. Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A. Influence
on Busilvex ® Pharmacokinetics of Clonazepam Compared to Previous
Phenytoin Historical Data. Anticancer Res .
2010;2984(30):2977-2984.
15. Nishikawa T, Yamaguchi H, Ikawa K, et al. Influence of
<scp>GST</scp>
polymorphisms on busulfan pharmacokinetics in Japanese children.Pediatr Int . 2019;61(6):ped.13859. doi:10.1111/ped.13859
16. Gibbs JP, Liacouras CA, Baldassano RN SJ. Up-regulation of
glutathione S-transferase activity in enterocytes of young children.Drug Metab Dispos . 1999;27(12):1466-1469.